

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

26 February 2015

Ms Kimberley Brown
Senior Adviser, Listings (Sydney)
ASX Compliance Pty Limited
20 Bridge Street
SYDNEY NSW 2000

(4 pages by email)

Dear Ms Brown

I refer to your letter dated 26 February 2015 querying the increase in Biotron Limited's ('the Company') share price from a close of \$0.13 on 20 February 2015 to \$0.16 today, together with an increase in the volume of securities traded and provide the following response:

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

No.

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

N/A.

3. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?

No. The Company notes that an ASX announcement 'Presentation to Investors' was made on 4 December 2014 covering the Company's ongoing activities and as advised to the ASX on 3 December 2014 the Phase 2 study (BIT225-008) of BIT225, the Company's lead antiviral drug, is fully recruited, with preliminary data expected late 1Q15. This is a key trial for the Company, designed to provide further safety and efficacy data in Hepatitis C genotype (HCV) 1 and 3 patients that demonstrates further safety and tolerability over 12 weeks of dosing. Previous studies have shown that BIT225 is able to eradicate HCV with 4 weeks dosing in combination with standard of care treatment, curing patients of their infection.

4. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

The Company confirms that it is, to the best of its knowledge and belief, in compliance with the Listing Rules and in particular, Listing Rule 3.1.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8028